Media - Homepage - Sanofi in Jordan

Events

2017

Sanofi Pasteur in the World Immunization Week

2016

Sanofi Jordan collaborates with the DRMS Launch of Deep Venous Thromboembolism Safety Zone

2016

First Diabetes and Ramadan International Alliance Forum towards a Safer and Healthier Ramadan

Press releases

June 24, 2022

Press releases

Press Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron

June 24, 2022

Press releases

Press Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine

Apr 30, 2018 • PDF
FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Apr 18, 2018 • PDF
Sanofi Jordan launches its Next Generation Basal Insulin Glargine U-300
Apr 3, 2018 • PDF
EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma
Apr 3, 2018 • PDF
EMA to review Dupixent® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma
Mar 29, 2018 • PDF
EMA to review sotagliflozin as potential treatment for type 1 diabetes

Mar 28, 2018 • PDF
Sanofi Completes Acquisition of Bioverativ Inc.
Mar 10, 2018 • PDF
Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need
Mar 10, 2018 • PDF
Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
Aug 3, 2018 • PDF
Sanofi Completes Acquisition of Bioverativ Inc.
Feb 23, 2018 • PDF
Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Bioverativ

Get in touch

Sanofi Aventis Groupe, Mecca Street, Al Hijaz Towers for Investment, 8th Floor
PO BOX 922464, Amman 11192 Jordan

(962) 6 55 63 6 60 Contactus.levant@sanofi.com